Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Elicio Therapeutics Inc.

Healthcare US ELTX

4.71USD
1.95(70.65%)

Last update at 2026-06-17T20:29:00Z

Day Range

2.866.64
LowHigh

52 Week Range

4.7014.93
LowHigh

Fundamentals

  • Previous Close 2.76
  • Market Cap224.06M
  • Volume50256176
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.51000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.57100M -51.89800M -35.19500M -28.20769M -26.40070M
Minority interest - - - - -
Net income -39.57100M -51.89800M -35.19500M -28.20769M -26.40070M
Selling general administrative 12.81M 11.33M 11.90M 5.63M 7.54M
Selling and marketing expenses - - - - -
Gross profit -1.12800M -1.17800M -1.17000M - -
Reconciled depreciation 1.13M 1.18M 1.17M 0.39M 0.25M
Ebit -37.71400M -51.44300M -34.13600M -23.66855M -25.47129M
Ebitda -36.58600M -50.26500M -32.96600M -23.27824M -25.21984M
Depreciation and amortization 1.13M 1.18M 1.17M 0.39M 0.25M
Non operating income net other - - - - -
Operating income -37.71400M -44.98600M -35.74500M -23.73338M -25.47469M
Other operating expenses 37.71M 44.99M 35.74M 23.73M 25.47M
Interest expense 1.13M 0.46M 1.06M 3.60M 0.88M
Tax provision 0.00000M 0.00000M 0.00000M - -
Interest income 0.78M 0.78M 0.37M 0.06M 0.00339M
Net interest income -0.35700M -3.18000M -0.68600M -3.53101M -0.87305M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 3.60M 0.88M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 36.59M 43.81M 34.58M 23.73M 25.47M
Cost of revenue 1.13M 1.18M 1.17M - -
Total other income expense net -1.85700M -6.91200M 0.55M -0.94330M -0.05296M
Discontinued operations - - - - -
Net income from continuing ops -39.57100M -51.89800M -35.19500M -28.20769M -26.40070M
Net income applicable to common shares - - - -28.20769M -26.40070M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25.86M 28.18M 27.15M 22.66M 14.81M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.75M 3.08M 0.17M 0.04M 0.09M
Total liab 24.23M 39.49M 15.77M 124.81M 89.35M
Total stockholder equity 1.64M -11.31200M 11.37M -102.14539M -74.53630M
Deferred long term liab - - - - -
Other current liab 6.43M 8.41M 0.04M 3.37M 2.96M
Common stock 0.18M 0.11M 0.10M 0.18M 0.17M
Capital stock 0.18M 0.11M 0.10M 0.18M 0.17M
Retained earnings -233.67200M -194.10100M -142.20300M -107.00825M -78.80056M
Other liab - - - 0.09M 0.03M
Good will - - - - -
Other assets - - - 3.45M -0.00300M
Cash 18.56M 17.62M 12.89M 6.16M 9.28M
Cash and equivalents - - - - -
Total current liabilities 8.11M 11.52M 9.77M 6.87M 18.88M
Current deferred revenue - 1.17M 4.45M - 2.45M
Net debt -4.05100M 8.42M -5.97700M 1.33M 2.52M
Short term debt 1.01M 0.90M 0.91M 0.69M 11.80M
Short long term debt - - - - 11.80M
Short long term debt total 14.51M 26.04M 6.92M 7.48M 11.80M
Other stockholder equity 235.26M 182.85M 153.68M 4.69M 4.09M
Property plant equipment - - - 8.50M 0.89M
Total current assets 19.31M 20.69M 16.35M 10.72M 10.36M
Long term investments - - - - -
Net tangible assets - - - -102.14539M -74.53630M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 9.41M 20.03M - - -
Inventory - - - - -
Accounts payable 0.67M 1.04M 4.37M 2.81M 1.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12700M -0.17500M -0.19700M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.77M 0.60M 3.52M 3.45M 3.57M
Deferred long term asset charges - - - - -
Non current assets total 6.55M 7.49M 10.80M 11.95M 4.46M
Capital lease obligations 5.11M 6.01M 6.92M 7.48M 0.00000M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.08400M -0.03200M -0.65384M -0.52536M
Change to liabilities - - - 1.12M 0.03M
Total cashflows from investing activities -0.01600M -0.08400M -0.03200M -0.65384M -0.52536M
Net borrowings 0.00000M 19.73M 10.00M - 14.68M
Total cash from financing activities 36.70M 42.32M 38.61M 21.20M 19.39M
Change to operating activities - - - -0.60735M 0.84M
Net income -39.57100M -51.89800M -35.19500M -28.20769M -26.40070M
Change in cash -0.23300M 5.19M 5.89M -1.63037M -5.07084M
Begin period cash flow 19.49M 14.30M 8.41M 10.04M 15.12M
End period cash flow 19.27M 19.49M 14.30M 8.41M 10.04M
Total cash from operating activities -36.95200M -37.06800M -32.69400M -22.17877M -23.93905M
Issuance of capital stock 25.39M 5.63M 7.00M 21.12M 5.05M
Depreciation 1.13M 1.18M 1.17M 0.39M 0.25M
Other cashflows from investing activities - 0.00300M 0.03M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - -0.54900M -0.15000M - -
Other cashflows from financing activities 36.70M 16.96M 21.76M -0.65384M 19.73M
Change to netincome - - - 5.12M 1.34M
Capital expenditures 0.02M 0.09M 0.07M 0.65M 0.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.44500M 3.96M -0.05700M 0.52M 0.87M
Stock based compensation 2.70M 1.45M 1.18M 0.58M 0.62M
Other non cash items 2.24M 8.24M 0.21M 3.60M 0.67M
Free cash flow -36.96800M -37.15500M -32.76000M -22.83260M -24.46440M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ELTX
Elicio Therapeutics Inc.		 1.95 70.65% 4.71 - - - 137.30 -2.6058
NVO
Novo Nordisk A/S		 -0.03 0.07% 43.52 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.49 1.12% 44.35 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.82 1.28% 458.99 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -6.8 1.11% 607.93 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Elicio Therapeutics Inc.

451 D Street, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Mr. Robert T. Connelly CEO, President & Director 1960
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 1966
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board NA
Mr. Brian Piekos Chief Financial Officer 1975
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources NA
Dr. Peter DeMuth Ph.D. Chief Scientific Officer 1986
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer NA
Ms. Esther Welkowsky Senior Vice President of Clinical Development NA
Ms. Joy Seymour VP & Head of Regulatory Affairs NA
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.